Fineline Cube

Follow:
14720 Articles
GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength
Company

GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength

Company

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength
Others

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength

BeOne Medicines' Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
CompanyDrug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

CompanyDrug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

CompanyDeals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Company

AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength

3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal
Company

3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline
CompanyDeals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

CompanyDrug

Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial

CompanyDrug

Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations